{"title": "Clinical trials", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2021-09-15", "cleaned_text": "disease || | |E.2 Objective of the trial objective of the trial || | |The objective will to analyze the cellular and humoral immunity against SARS-CoV-2 after administration of a third dose mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen. | |El objetivo ser\u00e1 el de analizar el desarrollo de inmunidad celular y humoral frente a SARS-CoV-2 tras la administraci\u00f3n de una tercera dosis de la vacuna mRNA-1273 (Moderna) en pacientes que han permanecido seronegativos tras la pauta est\u00e1ndar completa (dos dosis). | |E.2.2||Secondary objectives of the trial || | |- To development of cellular immunity against SARS-CoV-2 after 4 months of administration of a third dose of mRNA-1273 vaccine (Moderna). | - To establish baseline associated with biological non-response to vaccination. assess the safety and tolerability of the administration of the third dose of mRNA-1273 (Moderna) vaccine. |Analizar el desarrollo de inmunidad celular y humoral frente a SARS-CoV-2 tras 4 meses de la administraci\u00f3n de una tercera dosis de la vacuna mRNA-1273 (Moderna). | Establecer factores basales asociados a la no respuesta biol\u00f3gica a la vacunaci\u00f3n. Evaluar la seguridad y tolerabilidad de la administraci\u00f3n de la tercera dosis de la vacuna mRNA-1273 (Moderna). |E.2.3||Trial Male or female sex; 3. Renal transplant with stable renal function in the last 2 months prior to study inclusion; 4.Had received a full schedule mRNA1273 vaccine (Moderna) and remained seronegative o femenino; 3.Trasplante renal con funci\u00f3n renal estable en los \u00faltimos 2 meses previamente a la inclusi\u00f3n en el estudio; 4.Haber recibido pauta completa de vacunaci\u00f3n para SARS-CoV-2 con la vacuna mRNA1273 (Moderna) y haber permanecido seronegativos a las 2 semanas despu\u00e9s de la segunda dosis. 5.Paciente que otorgue el consentimiento informado por escrito |E.4||Principal exclusion criteria|| | |1. Renal or status; 3. Rejection treated the months; 4. Presence of humoral immunity to SARS-CoV-2 defined as the presence of specific IgM/IgG. |1.Trasplante renal < 3 meses; | 2.Estado de embarazo o lactancia; 3.Rechazo tratado en los \u00faltimos 6 meses; 4.Presencia de inmunidad humoral frente al SARS-CoV-2 definida como presencia de IgM/IgG espec\u00edficas. |E.5 End points | |E.5.1||Primary end point(s)|| | biological effectiveness by: | - Total antibody and IgG before (day 0) and after administration of the third dose (week subjected stimulus (day administration of the third dose (week +2) |La variable principal del estudio es evaluar la efectividad biol\u00f3gica mediante: | T\u00edtulo anticuerpos totales e IgG antes (d\u00eda 0) y despu\u00e9s de la administraci\u00f3n de la tercera dosis (semana +2). ELISpot de c\u00e9lulas T sometidas a est\u00edmulo antig\u00e9nicos de SARS-CoV-2 antes (d\u00eda 0) y despu\u00e9s de la administraci\u00f3n de la tercera dosis (semana +2); |E.5.1.1||Timepoint(s) of evaluation of this end point|| | |day 0 and week +2 | |D\u00eda 0 y semana +2 | |E.5.2||Secondary end point(s)|| | |- Total antibody and IgG at 4 months after the third dose. - ELISpot with anti-thymocyte globulins year, lymphopenia defined as transplantation < eGFR the patient, type of donor, BMI, ethnicity mild of the third dose. |T\u00edtulo anticuerpos totales e IgG a los 4 meses tras recibir la tercera dosis. | ELISpot de c\u00e9lulas T sometidas a est\u00edmulo antig\u00e9nicos de SARS-CoV-2 a los 4 meses tras recibir la tercera dosis. An\u00e1lisis de los factores basales asociados a la no respuesta biol\u00f3gica a la vacunaci\u00f3n, incluyendo factores demogr\u00e1ficos, comorbilidades, y asociados al trasplante: Sexo Tipo de trasplante (renal / renopancre\u00e1tico) Tratamiento con globulinas antitimoc\u00edticas durante el \u00faltimo a\u00f1o Limfopenia definida como < 1000/mm3 Tiempo del trasplante < 1 a\u00f1o eGFR (CKD-EPI) inmunosupresion basal de acuerdo al tratamiento recibido por el paciente, tipo de donante, BMI, etnia y grupo sanguineo. Porcentaje de pacientes que presentan acontecimientos adversos leves y/o graves tras la administraci\u00f3n de la tercera dosis |E.5.2.1||Timepoint(s) of evaluation of this end point|| | |E.6 and E.7 Scope of the trial | |E.6||Scope of the trial | |E.6.1||Diagnosis|| No | |E.6.2||Prophylaxis|| Yes | |E.6.3||Therapy|| No | |E.6.4||Safety|| No | |E.6.5||Efficacy|| No | |E.6.6||Pharmacokinetic|| No | |E.6.7||Pharmacodynamic|| No | |E.6.8||Bioequivalence|| No | |E.6.9||Dose response|| No | |E.6.10||Pharmacogenetic|| No | |E.6.11||Pharmacogenomic|| No | |E.6.12||Pharmacoeconomic|| No | |E.6.13||Others|| No Design of the trial | |E.8.1||Controlled|| No | |E.8.1.1||Randomised|| No | |E.8.1.2||Open|| Yes | |E.8.1.3||Single No | blind | No | | |E.8.2|| Comparator | product(s)|| |E.8.2.2||Placebo || No | |E.8.2.3||Other|| No | |E.8.3|| The trial involves single site in the Member State concerned || Yes | |E.8.4|| The Member |E.8.6.1||Trial being both the EEA|| |E.8.6.2||Trial conducted completely outside No has a data monitoring committee|| No | |E.8.8|| Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial || | |E.8.9 Initial estimate Member State concerned days|| | "}